Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

Àü¸³¼±ºñ´ëÁõ°ú ³²¼ºÇüÅ»¸ðÁõÀÇ ¿¬°ü¼º Association of Benign Prostate Hyperplasia with Male Pattern Baldness

´ëÇѺñ´¢±â°úÇÐȸÁö 1998³â 39±Ç 6È£ p.563 ~ 567
¼Ò¼Ó »ó¼¼Á¤º¸
¿ÀºÀ·Ä/Bong Ryoul Oh ±è¼ºÁø/¹®À絿/±èÇü³²/±Çµ¿µæ/¿ø¿µÈ£/·ù¼ö¹æ/¹Ú¾çÀÏ/Seong Jin Kim/Jai Dong Moon/Hyeung Nam Kim/Dong Oeuk Kwon/Young Ho Won/Soo Bang Ryu/Yang Il Park

Abstract

¼­·Ð
Àü¸³¼±ºñ´ëÁõ°ú ³²¼ºÇüÅ»¸ðÁõÀÇ º´Àο¡ ³²¼ºÈ£¸£¸ó°ú ³ëÈ­°¡ Áß¿äÇÑ ¿ªÇÒÀ» ÇÏ´Â °ÍÀ¸·Î
¾Ë·ÁÁ® ÀÖÀ¸³ª ±× ¿Ü ´Ù¸¥ ÀÎÀÚµéÀÌ ¾ó¸¶³ª °ü¿©ÇÏ´ÂÁö´Â ¾ÆÁ÷ Á¤È®È÷ ¹àÇôÁöÁö ¾Ê¾Ò´Ù. Àü
¸³¼±ºñ´ëÁõÀº »çÃá±â ÀÌÀü¿¡ °Å¼¼µÈ ³²ÀÚ¿¡¼­´Â ¹ß»ýÇÏÁö ¾Ê°í ´ëÇ¥ÀûÀÎ ³²¼ºÈ£¸£¸óÀÎ Å×½º
Å佺Å×·ÐÀÇ »ý»êÀ̳ª ±â´É¿¡ Àå¾Ö°¡ Àִ ȯÀÚ¿¡¼­´Â Àü¸³¼±ÀÌ Á¤»óÀûÀ¸·Î ¹ß´ÞÇÏÁö ¸øÇÑ´Ù
´Â »ç½ÇÀÌ ¿©·¯ ½ÇÇè¿¡¼­ ÀÔÁõµÇ¾ú´Ù. ¶ÇÇÑ ¼º¼±±â´ÉÀÌ ÀúÇÏµÈ ³²ÀÚ¿¡¼­´Â Å»¸ð°¡ µÇÁö ¾Ê
°í ÀÌ·± ȯÀÚ¿¡°Ô Å×½ºÅ佺Å×·ÐÀ» ÁÖÀÔÇϸé Å»¸ð°¡ À¯¹ßµÉ ¼ö ÀÖ´Ù°í º¸°íµÇ¾ú´Ù. Å×½ºÅ佺
Å×·ÐÀÇ »ê¹°ÀÎ dihydrotestosterone(DHT)Àº Àü¸³¼±ÀÇ ¹ß´Þ°ú ¼ºÀå, ³²¼º¿Ü¼º±âÀÇ ¹ß´Þ ¹×
³²¼ºÇüÀÇ ¾È¸éºÎ¿Í üºÎÀÇ ¸ð¹ß¼ºÀå°ú ³²¼ºÇüÅ»¸ðÁõ¿¡ ÇʼöÀûÀÌ´Ù. ¶ÇÇÑ ÀÌ DHT´Â
testosteroneÀÌ 5 alpha-reductase¿¡ ÀÇÇÏ¿© ȯ¿øµÇ¾î »ý»êµÇ¹Ç·Î 5 alpha-reductase°¡ Àü¸³
¼±ºñ´ëÁõ°ú ³²¼ºÇüÅ»¸ðÁõÀÇ ¹ß»ý¿¡ Áß¿äÇÑ ¿ªÇÒÀ» ÇÏ´Â °ÍÀ¸·Î ¾Ë·ÁÁ® ¿Ô´Ù. 5
alpha-reductase¸¦ ¾ïÁ¦ÇÏ´Â ¾à¹°¿¡ ´ëÇÑ ¿¬±¸´Â 1970³â´ë Á߹ݺÎÅÍ ½ÃÀ۵Ǿú°í 1980³â´ë¿¡
À̸£·¯ ¸î °¡Áö ¾à¹°ÀÌ °³¹ßµÇ¾úÀ¸¸ç À̵éÀº Ç÷û³» testosterone³óµµ¸¦ ´Ã¸®Áö ¾Ê°í DHT
Àdz󵵸¦ ³·Ãâ ¼ö ÀÖ°Ô µÇ¾ú´Ù. óÀ½À¸·Î 5 alpha-reductase¿¡ ´ëÇÑ ÀÓ»ó½ÇÇèÀ» ½ÃÇàÇÑ
finasteride(Proscar )¿¡ ´ëÇØ ¸¹Àº ¿¬±¸°¡ ÇàÇÏ¿©Á³°í ÃÖ±ÙÀÇ Àӻ󿬱¸¸¦ Åë
ÇØ Àü¸³¼±ºñ´ëÁõ¿¡ È¿°ú°¡ ÀÖÀ½ÀÌ ¹àÇôÁ³´Ù. ÃÖ±Ù¿¡´Â ÀÌ 5 alpha-reductase Inhibitor¸¦
DHT°ü·Ã ÁúȯÀÎ Á¶¸ðÁõ(hirsutism), ½É»ó¼º ÁÂâ ¹× ³²¼ºÇüÅ»¸ðÁõ¿¡µµ ÀÌ¿ëÇÏ·Á´Â ½Ãµµ°¡
ÀÌ·ç¾îÁö°í ÀÖ´Ù. Àΰ£¿¡¼­ 5 alpha-reductase´Â µÎÇÇ¿¡ dzºÎÇÑ 1Çü°ú Àü¸³¼±¿¡ dzºÎÇÑ 2Çü
ÀÇ µÎ °¡Áö isoenzymeÀÌ È®ÀεǾú´Ù. ³²¼ºÇü °¡¼º¹ÝÀ½¾ç ȯÀÚ´Â 2ÇüÀÇ 5 alpha-reductase
°áÇÌÁúȯÀε¥ ÀÌ isoenzymeµµ Å»¸ðÀÇ ÁøÇà¿¡ ¿µÇâÀ» ÁØ´Ù°í º¸°íÇÏ¿´´Ù. ¶ÇÇÑ, 1ÇüÀÇ
isoenzymeµµ Àü¸³¼±ÀÇ À¯Áö¿¡ ¾î´À Á¤µµ ¿ªÇÒÀ» ÇÑ´Ù´Â ÁÖÀåµµ ÀÖ´Ù. °¢°¢ÀÇ isoenzymeÀÇ
Àü¸³¼±°ú µÎÇÇ¿¡ ´ëÇÑ ¿ªÇÒÀº ÇöÀç È°¹ßÇÑ ¿¬±¸ ÁßÀÌ´Ù. ±×·¯³ª, Àü¸³¼±ºñ´ëÁõ°ú ³²¼ºÇüÅ»¹¦
ÁõÀÇ ¿ªÇÐÀû °ßÁö¿¡¼­ÀÇ »óÈ£ °ü°è¿¡ ´ëÇؼ­´Â ¾Ë·ÁÁø ¹Ù°¡ ¾ø´Ù ÀÌ¿¡ ÀúÀÚµéÀº Àü¸³¼±ºñ´ë
Áõ°ú ³²¼ºÇüÅ»¸ðÁõ°úÀÇ ¿¬°ü¼ºÀ» Æò°¡ÇÏ°íÀÚ ÇÑ´Ù.
#ÃÊ·Ï#
Purpose : Both benign prostate hyperplasia(BPH) and male pattern baldness
(androgenic alopecia) share the pathogenesis of androgen dependent disorder in addition
to afflict large population of old men with chronobiological progress. However, it is
unclear that both diseases relate to each other on epidemiologic basis. We evaluated the
frequency and severity of male pattern baldness between the patients with BPH and
control group.
Materials and Methods : A total of 225 patients with BPH(mean age: 69.3¡¾6.5years)
and 160 controls(mean age: 68.5¡¾6.4 years), whose age over 60, was included in this
study. The estimation of bladness severity was based on the Norwood's
classification(grade 1 to VII). International prostate symptom score (IPSS) and genetic
tendency of baldness were also evaluated. The difference of IPSS and grade of baldness
between two groups were analysed by Mann-whitney test and the frequency of
inherited baldness were compared by Chisquare test. Correlations between severity of
baldness and IPSS of each
group were estimated by Spearman's rank correlation method.
Results : It was noted that the patients with BPH had an apparent higher grade of
male pattern baldness in comparison with that of controls(median value of IV to 111,
p<0.001). The proportion of male pattern baldness with grade IV or greater in BPH
group was significantly larger than that of controls(53.8% versus 36.9%, p<0.01). There
was greater frequency of inheritant baldness in BPH group than in controls(31.6%
versus 12.5%, p<0.001). No significant correlations were noted between baldness severity
and IPSS in both groups.
Conclusions : Our study demonstrated there was a strong association of BPH with
male pattern baldness. (Korean J Urol 1998; 39: 563¡­7)

Å°¿öµå

Benign prostate hyperplasia; Baldness;

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

   

µîÀçÀú³Î Á¤º¸

KCI
KoreaMed
KAMS